Mylan Announces Final FDA Approval for Doxycycline Tablets
Posted on: Wednesday, 8 November 2006, 09:01 CST
PITTSBURGH, Nov. 8 /PRNewswire-FirstCall/ -- Mylan Laboratories Inc. today announced that Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Doxycycline Tablets, 50mg, 75mg and 100mg.
Doxycycline Tablets are a generic version of Doak Dermatologics' Adoxa(R) Tablets (manufactured by Par Pharmaceuticals). Doxycycline Tablets had U.S. sales of approximately $56 million for the three strengths approved for the 12-month period ended June 30, 2006, according to IMS Health.
This product will be shipped immediately.
Mylan Laboratories Inc. is a leading pharmaceutical company with three principal subsidiaries: Mylan Pharmaceuticals Inc., Mylan Technologies Inc. and UDL Laboratories Inc. Mylan develops, licenses, manufactures, markets and distributes an extensive line of generic and proprietary products.
For more information about Mylan, please visit http://www.mylan.com/.
Mylan Laboratories Inc.
CONTACT: Patrick Fitzgerald or Kris King of Mylan Laboratories Inc.,+1-724-514-1800
Web site: http://www.mylan.com/
Source: PRNewswire-FirstCall
Related Articles
- ABC Laboratories Announces Pharmaceutical Program Management
- Schaeffer's Upon Further Review Highlights the Following Stocks: Amazon.Com, Google, eBay, Travelzoo, and Mylan Laboratories
- United Research Laboratories/Mutual Pharmaceutical Company Formally Notifies Adams Respiratory Therapeutics of Its ANDA Filing for Guaifenesin Extended-Release Tablets, 600 Mg and 1200 Mg
- United Research Laboratories/Mutual Pharmaceutical Company Announce ANDA Filing for Guaifenesin Extended-Release Tablets, 600 Mg and 1200 Mg
- Mylan Laboratories Appoints Carolyn Myers, Ph.D., President of Mylan Technologies Inc.
- Mylan Laboratories and Forest Laboratories Announce Nebivolol Licensing Agreement
- Mylan Laboratories Inc. Reports Positive Development From FDA Advisory Committee Vote on EMSAM(R)
- Mylan Laboratories Inc. Announces Executive Appointments
- Agvar Chemicals Sues Barr Laboratories, Teva Pharmaceuticals USA in Connection With Barr's Generic Alternative to Allegra(R)
- Drugmaker Mylan Laboratories Reports Decline in Earnings, Revenue
 |
 |
User Comments (0)
RSS Feeds